
Summit Therapeutics(SMMT.O)股价在周一盘前交易中下跌近20%,此前美国食品药品监督管理局拒绝批准其实验性肺癌药物依沃西单抗。
Shares of Summit Therapeutics (SMMT.O) fell nearly 20% in premarket trading on Monday after the US Food and Drug Administration declined to approve its experimental lung cancer drug ivonescimab.
监管机构周日表示,在作为Summit上市申请一部分的晚期研究中,该药物未能在总生存期这一衡量长期治疗获益的关键指标上达到统计学显著性。
The regulator on Sunday cited the drug's failure to achieve statistical significance in overall survival, a key measure of long-term treatment benefit, in a late-stage study that formed part of Summit's marketing application.
BMO Capital分析师Evan Seigerman表示,这一决定为该药物类别确立了“有意义的监管先例”,对百时美施贵宝(BMY.N)、BioNTech(22UAy.DE)、辉瑞(PFE.N)、默克(MRK.N)和艾伯维(ABBV.N)正在开发的类似候选药物具有潜在影响。
The decision establishes a "meaningful regulatory precedent" for the drug class, with potential implications for similar drug candidates being developed by Bristol-Myers Squibb (BMY.N), BioNTech (22UAy.DE), Pfizer (PFE.N), Merck (MRK.N) and AbbVie (ABBV.N), said BMO Capital analyst Evan Seigerman.
依沃西单抗旨在阻断两种蛋白:PD-1(帮助癌细胞逃避免疫系统)和VEGF(肿瘤利用其生长血管)。Summit股价在开盘前下跌19.9%,报11.33美元。
Ivonescimab is designed to block two proteins: PD-1, which helps cancer evade the immune system, and VEGF, which tumors use to grow blood vessels. Summit's shares were down 19.9% at $11.33 before the bell.
该公司曾寻求批准依沃西单抗联合化疗,用于治疗携带EGFR基因突变、既往接受过治疗的晚期非鳞状非小细胞肺癌(NSCLC)患者。
The company had sought approval for ivonescimab, in combination with chemotherapy, for previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) carrying EGFR genetic mutations.
根据美国肺脏协会数据,该病症是最常见的肺癌类型,EGFR突变在美国病例中占比10%至15%。
The condition is the most common type of lung cancer, with the EGFR mutation occuring in 10% to 15% of cases in the US, according to the American Lung Association.
TD Cowen分析师在该决定公布后表示,FDA的决定与该机构此前设定的高标准一致。
The FDA's decision was consistent with the high bar the agency had previously set, TD Cowen analysts said after the move.
分析师目前正密切关注预计将于今年晚些时候公布的另一项晚期研究数据,该研究测试了该药物联合化疗作为NSCLC患者一线治疗的疗效。
Analysts are now closely watching data from a separate late-stage study expected later this year, in which the drug in combination with chemotherapy was tested as a first-line treatment for patients with NSCLC.
TD Cowen分析师表示,FDA周日的拒批决定不影响依沃西单抗在一线NSCLC治疗中的成功概率,“后者仍然是规模大得多且更为重要的商业机会”。
The FDA's rejection on Sunday does not impact the probability of success for ivonescimab in first-line NSCLC, "which remains the substantially larger and more important commercial opportunity," TD Cowen analysts said.
Summit 2022 年从中国的康诺亚(9926.HK)手中获得了该药物在美国、加拿大、欧洲和日本的权益,交易价值最高可达 50 亿美元。康诺亚保留了中国及其他市场的权益。
Summit acquired rights to the drug in the US, Canada, Europe and Japan from China's Akeso (9926.HK) in 2022 under a deal valued at up to $5 billion. Akeso retained rights in China and other markets.